Article: Affects serotonin, norepinephrine: FDA approves duloxetine for the treatment of major depressive disorder.(News)

Approval of duloxetine hydrochloride by the Food and Drug Administration offers an additional drug for the treatment of major depressive disorder that affects both serotonin and norepinephrine.

In a statement announcing the approval, Dr. Stephen M. Stahl said duloxetine (Cymbalta), manufactured by Eli Lilly & Co., "offers physicians a new opportunity to help patients with depression, particularly those who experience the common physical symptoms of the disease, such as vague aches and pains."

But duloxetine "is not an analgesic, and it would be wrong to characterize it that way," Dr. Stahl told this newspaper.

Like selective serotonin reuptake ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!